Travere Therapeutics, Inc. (TVTX)
A
Pipeline Grade
Financial Position (from SEC Filings)
$78.4M
Cash & Equivalents
$40.4M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$4,432M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
SPARSENTAN
FILSPARI |
APPROVED | Acid Sphingomyelinase Deficiency, Alport Syndrome, ANCA Associated Vasculitis, Anxiety, Autoimmune Diseases, Cardiovascular Diseases, Cerebrotendinous Xanthomatosis, Cerebrotendinous Xanthomatosis (CTX), Ceroid Lipofuscinosis, Neuronal, 2, Depressive Symptoms, Fabry Disease, Focal Segmental Glomerulosclerosis, Gaucher Disease, Glomerulonephritis, Glomerulonephritis, IGA, GM1 Gangliosidosis, Healthy Subjects, Homocystinuria, Homocystinuria Due to CBS Deficiency, IgA Vasculitis, Immune System Diseases, Immunoglobulin A (IgA) Nephropathy, Immunoglobulin A Nephropathy, Kidney Diseases, Kidney Transplant, Lysosomal Acid Lipase Deficiency, Metachromatic Leukodystrophy, Minimal Change Disease, Mucopolysaccharidosis II, Mucopolysaccharidosis III-B, Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI, Mucopolysaccharidosis VII, Niemann-Pick Disease, Type C, Pantothenate Kinase-Associated Neurodegeneration, Post-traumatic Stress Disorder, Problems Psychosocial, Proteinuria, Proteinuria in Nephrotic Range, Proteinuric |
Upcoming Catalysts
No upcoming catalysts detected for this company.